Circulating CD34+ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT

Bone Marrow Transplantation

Volumn 47, Issue 1, 2012, Pages 143-145

  Alchalby, H ^a   Lioznov, M ^a   Fritzsche Friedland, U ^a   Badbaran, A ^a   Zabelina, T ^a   Bacher, U ^a   Stubig T ^a   Ayuk, F A ^a   Zander, A R ^a   Kroger N ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; BLAST CELL; CD34 HEMATOPOIETIC PROGENITOR CELL; CD34 SELECTION; CERVANTES SCORE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; JAK2 GENE; LETTER; LILLE SCORE; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MICROCHIMERISM; MYELOFIBROSIS; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SCORING SYSTEM; SPLEEN SIZE; THROMBOCYTHEMIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD34; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROGNOSIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855719730     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.17     Document Type: Letter

References (8)

1. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009; 115: 3842-3847.
2. Andreasson B, Swolin B, Kutti J. Patients with idiopathic myelofibrosis show increased CD34+ cell concentrations in peripheral blood compared to patients with polycythaemia vera and essential thrombocythaemia. Eur J Haematol 2002; 68: 189-193. (Pubitemid 34717818)
3. Douer D, Fabian I, Cline MJ. Circulating pluripotent haemopoietic cells in patients with myeloproliferative disorders. Br J Haematol 1983; 54: 373-381. (Pubitemid 13054559)
4. Hibbin JA, Njoku OS, Matutes E, Lewis SM, Goldman JM. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol 1984; 57: 495-503. (Pubitemid 14082100)
5. Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001; 98: 3249-3255.
6. Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients. Br J Haematol 2005; 128: 42-48.
7. Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264-5270.
8. Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2V617F-mutation status, allele burden and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116: 3572-3581.